Yunkang Group Limited

Equities

2325

KYG9889T1067

Healthcare Facilities & Services

Market Closed - Hong Kong S.E. 04:08:16 2024-04-24 am EDT 5-day change 1st Jan Change
11.06 HKD 0.00% Intraday chart for Yunkang Group Limited 0.00% -10.08%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Everbest Machinery Industry to Set Up 30 Million Yuan Joint Venture MT
Yunkang Swings to Loss in 2023; Recommends Dividend MT
Yunkang Group Limited Proposes Final Cash Dividend for the Financial Year End 31 December 2023 CI
Yunkang Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Yunkang Group Expects a Loss of Up to 130 Million Yuan for Full Year 2023 MT
Yunkang Group Limited Provides Consolidated Earnings Guidance for the Year Ended December 31, 2023 CI
Yunkang Group's H1 Attributable Profit Plunges on Lower Revenue MT
Yunkang Group Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Yunkang Group Limited Announces Director Changes CI
Yunkang's Profit to Drop Up to 83% in H1 MT
Yunkang Group Limited Approves Final Dividend for the Year Ended December 31, 2022, Payable on August 25, 2023 CI
Yunkang Group Limited Approves Final Dividend for the Year Ended December 31, 2022 CI
Alibaba Names Successors to Chairman & CEO MT
Certain Ordinary Shares of Yunkang Group Limited are subject to a Lock-Up Agreement Ending on 17-MAY-2023. CI
Over 200,000 Firms Want to Test Alibaba's AI Chatbot MT
Yunkang Group Limited Declares Final Dividend for the Year Ended 31 December 2022 CI
Yunkang Group Limited Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Disillusioned at home, super-rich Chinese set their sights on Singapore RE
Yunkang Group Limited(SEHK:2325) added to S&P Global BMI Index CI
Certain Ordinary Shares of Yunkang Group Limited are subject to a Lock-Up Agreement Ending on 17-NOV-2022. CI
Yunkang's H1 Net Profit Grows 50% to $34.8 Million MT
Yunkang Group Limited Announces Interim Dividend for the Six Months Ended 30 June 2022 CI
Yunkang Group Limited Declares an Interim Dividend for the Six Months Ended June 30, 2022, Will Be Paid Before September 30, 2022 CI
Yunkang Group Limited Announces Executive Changes CI
Yunkang Says Public Float 'Sufficient' after Hong Kong Regulator Warning MT
Chart Yunkang Group Limited
More charts
Yunkang Group Ltd is a China-based Company mainly engaged in the provision of diagnosis testing services. The Company operates three segments. Diagnosis Testing segment provides diagnosis testing to hospital and non-medical clients, mainly including routine diagnostic testing, routine pathological examination, infectious disease diagnostic testing, genetic disease diagnostic testing and early cancer detection. Hospital Management Business segment provides management services for the community clinics. Research & Development Institution segment is engaged in the research and development of testing kits. The Company primarily provides services for hospitals and other medical institutions, and commercial entities such as financial institutions and insurance companies.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
10.23 CNY
Average target price
12.93 CNY
Spread / Average Target
+26.43%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 2325 Stock
  4. News Yunkang Group Limited
  5. Yunkang's H1 Net Profit Grows 50% to $34.8 Million